sellWeak cluster of 610b5-1 plan
Henry E. Pelish sold $895k of NUVL
Chief Scientific Officer at Nuvalent, Inc.. 10,070 shares at an average of $88.84, traded Oct 13, 2025, filed Oct 15, 2025.
Warning score
24Value
$895k
10,070 shares
Holdings after
65,963
-14% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +24Trade size$895k at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-240310, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 13, 2025 | MOption exercise Class A Common Stock10b5-1 | +1,669 | $18.93 | $32k | 67,632 | Oct 15, 2025 |
| Oct 13, 2025 | MOption exercise Class A Common Stock10b5-1 | +4,168 | $27.85 | $116k | 71,800 | Oct 15, 2025 |
| Oct 13, 2025 | MOption exercise Class A Common Stock10b5-1 | +1,800 | $72.35 | $130k | 73,600 | Oct 15, 2025 |
| Oct 13, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -7,637 | $89.81 | $686k | 65,963 | Oct 15, 2025 |
| Oct 14, 2025 | MOption exercise Class A Common Stock10b5-1 | +731 | $18.93 | $14k | 66,694 | Oct 15, 2025 |
| Oct 14, 2025 | MOption exercise Class A Common Stock10b5-1 | +877 | $27.85 | $24k | 67,571 | Oct 15, 2025 |
| Oct 14, 2025 | MOption exercise Class A Common Stock10b5-1 | +825 | $29.33 | $24k | 68,396 | Oct 15, 2025 |
| Oct 14, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -1,167 | $84.98 | $99k | 67,229 | Oct 15, 2025 |
| Oct 14, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -866 | $86.11 | $75k | 66,363 | Oct 15, 2025 |
| Oct 14, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -400 | $87.39 | $35k | 65,963 | Oct 15, 2025 |
| Oct 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,669 | $0.00 | $0 | 14,968 | Oct 15, 2025 |
| Oct 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,168 | $0.00 | $0 | 21,528 | Oct 15, 2025 |
| Oct 13, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,800 | $0.00 | $0 | 27,100 | Oct 15, 2025 |
| Oct 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -731 | $0.00 | $0 | 14,237 | Oct 15, 2025 |
| Oct 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -877 | $0.00 | $0 | 20,651 | Oct 15, 2025 |
| Oct 14, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -825 | $0.00 | $0 | 14,025 | Oct 15, 2025 |
Related signals
Other insiders at Nuvalent, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | Nuvalent, Inc. | Henry E. Pelish Chief Scientific Officer | $261k 2,111 shares | -3% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $3.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.4M 11,430 shares | -12% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.8M 23,000 shares | -28% | |
| 16Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $679k 5,500 shares | -9% | |
| 30Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $2.5M 20,000 shares | -26% | |
| 30Weak | Nuvalent, Inc. | James Richard Porter President and CEO | $2.7M 30,000 shares | -8% | |
| 32Weak | Nuvalent, Inc. | Alexandra Balcom Chief Financial Officer | $1.1M 11,430 shares | -12% | |
| 14Weak | Nuvalent, Inc. | Deborah Ann Miller Chief Legal Officer | $593k 5,500 shares | -8% | |
| 14Weak | Nuvalent, Inc. | Darlene Noci Chief Development Officer | $593k 5,500 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.